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Abstract
The aim of this work is to enhance the dissolution of furosemide, a hydrophobic drug used in treating hypertension. Solid 
dispersion via lyophilisation was employed for this purpose. Sugar and oligosaccharide, trehalose and hydroxyl propyl-
γ-cyclodextrin (HP-γ-CD), were used as carrier molecules. Complexation of drug molecules with cyclodextrins changes 
its physical properties, including solubility. Trehalose was selected as it is a hydrophilic molecule as well as it reduces the 
cellular oxidative stress. Binary solid dispersions at three weight ratios drug to sugar/oligosaccharide were prepared. Solid 
dispersions were compared with unprocessed drug molecules and the marketed product. Samples were characterized via 
Fourier transform infrared spectroscopy, differential scanning calorimetry and In vitro drug dissolution. All lyophilized 
samples showed a significant improvement (p < 0.05) in furosemide dissolution in the aqueous dissolution medium. The 
study introduces furosemide/HP-γ-CD and furosemide/trehalose freeze dried composites as potential candidate powders to 
formulate for example fast disintegrating tablets. 
Keywords:  Furosemide; Trehalose; Solid dispersion; Lyophilisation; Cyclodextrin
Abbreviations: BCS: Biopharmaceutical Classification 
System; CDs: Cyclodextrins; FT-IR: Fourier Transform Infra-
Red spectroscopy; DSC: Differential Scanning Calorimetry
Introduction
Poor aqueous solubility of certain drugs is one of the 
most significant challenges in drug development process. 
It is one of the key factors that controls dissolution rate, 
and hence is expected to affect the bioavailability of the 
therapeutic agent [1]. The oral route of drug administration 
is the most convenient for drug delivery because of its 
ease of administration with high patient compliance and 
is considered to be cost-effective. For efficient drug action 
after oral administration, the drug particles must be first 
dissolved in the gastrointestinal fluids prior to being 
absorbed into the systemic circulation. Incomplete drug 
absorption of certain candidates from the intestines leads 
to interruption in drug distribution, reduced bioavailability 
and therapeutic failures [2]. The oral bioavailability for drugs 
relies on a few factors, including solubility and dissolution in 
the gastrointestinal fluids, drug permeability across the gut 
barriers, and metabolism by enzymes. The most common 
causes of low oral bioavailability are resulted from poor 
solubility and/or low permeability of certain drugs [3]. 
Poorly water-soluble drugs often require high doses to reach 
therapeutic plasma concentrations after oral administration 
[4]. According to the Biopharmaceutical Classification 
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System (BCS), class II drugs have high permeability and low 
solubility, where the bioavailability of these agents is limited 
by their dissolution rate. Furosemide (Figure 1A) is a model 
BCS Class IV hydrophobic agent that suffers incomplete and 
variable bioavailability due to its limited aqueous solubility 
and permeability. 
Many approaches have been tried to improve the 
dissolution of poorly water soluble therapeutics such as 
using liquisolid techniques [5-7], solid dispersions [8], 
nanosuspensions [9], liposomes [10] and complexation with 
cyclodextrins [11].
Cyclodextrins (CDs) are oligosaccharides arranged in a 
cyclic form with the hydrophilic surface oriented outwards. 
This gives CDs their unique lipophilic central cavity that can 
accommodate lipophilic molecules via complex formation. 
This complex formation can modify physical properties 
of lipophilic molecules, including aqueous drug solubility. 
Usually, substituted CDs were prepared to overcome the 
limited solubility of natural CD [12]. hydroxyl-propyl-γ-
cyclodextrin (HP-γ-CD) is one such example of substituted 
CD (Figure 1B). Based on the unique ability of CDs to a 
accommodate guest molecules in their internal cavity, 
they have been successfully used to increase solubility of 
hydrophobic drugs [13].
Trehalose is widely used as a carrier to increase 
protein stability, based on its chemical structure (Figure 
1C). Recently it was reported that oxidative stress is a key 
factor in the pathogenesis of hypertension [14]. Exposure of 
cells to reactive oxygen species, such as hydrogen peroxide, 
can cause oxidative damage to amino acids in the cellular 
proteins, and trehalose accumulation was found to reduce 
such damage [15]. Therefore, trehalose was selected as 
carrier to furosemide based on many reasons. First, being 
hydrophilic sugar it is expected to increase wettability and 
consequently solubility of lipophilic drugs. Other sugars, 
such as sucralose, were investigated as potential solubility 
modifier with reported success [16]. Secondary, due to 
its protection against oxidative stress that may augment 
furosemide effect in controlling hypertension. 
Figure 1: Chemical structure of furosemide (a), 
2-hydroxypropyl-γ-cyclodextrin (b), and Trehalose (c).
In this study, the aim was to improve furosemide 
dissolution rate via hydrophilic sugars employing solid 
dispersion technique, namely freeze drying. Sugars are 
known to enhance dissolution of poorly water-soluble drugs 
[17]. However due to the sparse literature, HP-γ-CD and 
Trehalose were chosen to confirm the suitability of those 
specific carriers to enhance hydrophobic drug dissolution. 
Materials and Methods
Materials
Furosemide, 2-hydroxypropyl-γ-cyclodextrin, trehalose 
were obtained from Sigma-Aldrich (Dorset, UK). Other 
chemicals were of analytical grade and used as obtained.
Methods
Preparation of furosemide freeze dried formulations: 
Solid dispersion formulations of furosemide were prepared 
employing freeze drying technique. Binary solid dispersion 
of the drug and the hydrophilic excipients were prepared at 
different weight ratios according to compositions shown in 
Table 1. 
Formula* Furosemide (gm) Cyclodextrin (gm) Trehalose (gm) Q10 Q90
control 13.8±0.7 42.2±0.4
FCD1 1 1 84.5±0.8 97.9±0.8
FCD2 1 2 94.8±0.4 98.9±0.2
FCD3 1 5 95.1±0.7 99.2±0.2
FT1 1 1 64.5±5.2 93.8±0.3
FT2 1 2 39.3±4.1 91.1±3.3
FT3 1 5 55.4±0.1 99.9±0.3
Marketed product - - - 63.0±0.4 90±0.7
Table 1: Compositions of solid dispersions of furosemide with the chosen hydrophilic excipients 
* FCD is formulae with cyclodextrin
*FT is formulae with trehalose
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Drug and carrier were dissolved in 1:1 ethanol: water 
ratio (this ratio was chosen as it has resulted in a complete 
solubilisation of the powder). The obtained solutions were 
subjected to freezing at −85◦C for 24 hours before subjecting 
to lyophilization (VirTis freeze drier, BioPharma, Boston, MA, 
USA). Shelf temperature was kept at 20◦C under pressure of 
18mBar.
Characterization of furosemide formulations
•	 Fourier Transform Infra-Red Spectroscopy (FT-IR) 
Fourier Transform Infra-Red spectroscopy (FT-IR) was 
conducted for the unprocessed furosemide, pure hydrophilic 
excipients and their binary solid dispersion formulations. 
Small amounts of all samples were used. The spectra were 
measured over the range between 4000–500 cm−1, and the 
resolution used was 4 cm−1 using FTIR spectrophotometer 
(SHIMADZU, Buckinghamshire, UK). 
•	 Differential Scanning Calorimetry (DSC)
The thermal behavior of unprocessed furosemide, pure 
hydrophilic excipients and their binary solid dispersions 
were investigated using DSC (Q 1000 TA, TA Instruments, 
Ghent, Belgium). Samples, each weighing about 3 mg, were 
loaded into aluminum pans and hermetically sealed, using 
empty pan as reference. The test and reference pans were 
heated simultaneously from 0 to 300oC at a heating rate of 
10oC/minute. 
•	 Dissolution Studies
In vitro drug dissolution studies were performed on the 
lyophilized formulations and unprocessed furosemide drug 
powders (20mg) as control. The dissolution tests were 
performed using USP dissolution apparatus type II (Caleva 
Ltd., Dorset, UK). In this method, 900 mL distilled water was 
used as a dissolution medium (as the aim of the study was 
to test drug aqueous dissolution characteristics in water 
as a general aqueous medium). The samples (equivalent to 
20mg of the drug) were loaded into the dissolution vessels. 
Temperature was kept at 37 ± 1 °C and the medium was 
stirred at a paddle speed of 100 rpm (13). Ten milliliters of 
the samples were collected at intervals of 5, 10, 15, 20, 25, 30, 
45, 60 and 90 min and were replaced by 10 mL to maintain a 
constant volume. Then the collected samples were analysed 
spectrophotometrically at 274 nm using M501 single 
beam scanning ultra-violet spectrophotometer (Spectronic 
Tudor, Leeds, UK). All the dissolution tests were performed 
in triplicates. For comparison, the marketed product 
(Furosemide 20mg, Bristol LTD) was used to evaluate our 
formulations.
Stability studies
In this study, the accelerated stability study was 
performed to study the effect of ageing on furosemide in 
selected formulations. Samples were stored in stability 
cabinet with conditions of 40 ± 2°C/75% ± 5% RH for 6 
months, and their properties were examined by conducting 
dissolution studies. 
Statistical analysis
All data obtained from the evaluation of solid dispersions 
were subjected to the appropriate statistical analysis, 
using student t-test, to determine their significances. The 
significance level used was 0.05, and results are regarded as 
significant when P-value is less than 0.05.
Results and Discussion
Characterisation of Furosemide Freeze Drier 
Formulations 
Differential scanning calorimetry (DSC): Thermal pattern 
of furosemide before and after processing with different 
excipients were investigated. The collected thermograms are 
shown in Figure 2. 
Figure 2: DSC thermograms of furosemide and different freeze dried formulations prepared using HP-γ-CD (A) and trehalose 
(B). Detailed formulations are in Table 1.
Open Access Journal of Pharmaceutical Research4
Elkordy AA, et al. Insights into the Effect of Trehalose and Cyclodextrin Molecules on Dissolution 
Characteristics of Furosemide Lyophilised Powder. Pharm Res 2020, 4(2): 000205.
Copyright©  Elkordy AA, et al.
DSC was used for the investigation of any interaction 
between the drug and the used excipients. The DSC 
thermogram for unprocessed furosemide showed two peaks, 
one is a sharp exothermic peak at 223.08°C with high enthalpy 
of 270.1 J/g corresponds to its melting transition (Tm) and 
reflects its crystalline nature. A second endothermic peak 
was noticed at about 269.62°C that may correspond to its 
degradation. This thermogram is similar to published data 
for the same drug [18]. Any change in the position or the 
intensity of these two peaks could be taken as changes in the 
physical or chemical characteristics of the drug.
Lyophilization of furosemide with cyclodextrin resulted 
in shifting of the main transition peak of furosemide to 
lower Tm with the peak becoming broader with reduced 
sharpness. This accompanied by reduction in the melting 
enthalpy. Increasing cyclodextrin concentration in FCD3 
(1:5 drug to cyclodextrin, respectively) resulted in complete 
abolish of the drug main transition peak indicating possible 
complete drug amorphousization arising from the fact that 
drug is molecularly entrapped in the cavity of CD. It worth 
noting that the melting transition is immediately followed by 
endothermic event. This could be due to the decomposition 
of the newly formed complex. These finding were previously 
reported by other investigators and were similarly explained 
[19].
For furosemide/trehalose freeze dried samples, the 
thermograms showed two thermal events. The first is an 
endothermic peak at about 93ͦ°C that corresponds to melting 
transition of trehalose [20]. This indicates that trehalose was 
in the dehydrate form [21]. The second is for the melting of 
furosemide that was shifted to lower temperature (210°C). 
As the concentration of trehalose increases, the transition 
peak of the drug becomes smaller and more broader with 
Tm of 206.6°C. This can indicate reduced drug crystalinity 
or weakening of the crystalline structure of the drug with 
possible development of amorphous form. At the highest 
ratio of trehalose, the thermal event showed further 
broadening with peak sharpening markedly reduced. This 
could indicate transformation of appreciable amount of the 
drug to the amorphous state. 
Fourier transform infra-red spectroscopy (FT-IR) results: 
The structural features of furosemide were identified using 
FTIR before and after processing. The spectra (data not 
shown) reflected the characteristic peaks for unprocessed 
drug and different formulations. Pure furosemide showed 
a characteristic absorption bands at 3350 cm−1 which is 
assigned to the NH2 stretching vibration of -NHCH2, another 
band at 3260 cm−1 due to stretching vibration of SO2NH2 and 
band 1660 cm−1 assigned to the bending vibration of the 
amino group. The band due to the asymmetric stretching 
vibration of the carbonyl group is noticed at 1560 cm−1 
and the 1318 cm−1 band is for the asymmetric stretching 
vibration of the sulfonyl group in furosemide structure. The 
drug spectrum is similar to the previously reported drug 
spectrum [18,22].
Regarding the spectra of different freeze dried 
formulations using different excipients, the main 
characteristic peaks of furosemide can be detected (data not 
shown). This indicates that there is no interaction between 
the hydrophilic excipients and the drug.
In Vitro Drug Dissolution Testing
The dissolution profiles of furosemide released from 
different formulations are presented in Figure 2. The 
dissolution parameters taken as percentage amount released 
after 10 minutes (Q10) and total percentage drug released 
after 90 minutes (Q90) are presented in Table 1. The 
dissolution pattern of unprocessed furosemide showed slow 
and incomplete drug dissolution with Q10 of only 13% with 
an overall release of 42% of the loaded dose at the end of the 
dissolution study. This dissolution behavior can be explained 
based on the poor drug solubility. 
Figure 3: In vitro dissolution profiles of furosemide and freeze dried formulations prepared using hydroxyl propyl-γ-
cyclodextrin (A) and trehalose (B). For formulation detail refers to Table 1. Standard error bar, if not shown, are embedded 
within the symbol.
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Freeze dried formulations using HP-γ-CD significantly 
(P < 0.05) increased furosemide dissolution (Figure 3). The 
extent of enhancement correlated to the proportion of HP-γ-
CD in the solid dispersion. At 1:1 ratio (formula FCD1), about 
50% of the loaded drug was liberated after 5 minutes that 
was increased to 83% after 10 minutes (Q10) giving rise to 
about 6-fold enhancement in drug dissolution, compared to 
unprocessed. Increasing HP-γ-CD proportion to 1:2 slightly 
increased dissolution parameters relative to FCD1. However, 
for FCD3 (1:5 drug: HP-γ-CD) there was a prompt release 
of 83 and 94% after 5 and 10 minutes, respectively. Such 
high initial drug release is very advantageous when fast 
disintegrating solid dosage form is required. The improved 
dissolution could be due to reduced drug crystalline nature 
as the drug is now molecularly dispersed in the cavities of 
HP-γ-CD molecules. This suggestion is supported by the 
DSC data. This entrapment takes place by hydrogen bond 
formation between the hydroxyl groups of CDs and the 
carboxylic and/or amino groups of furosemide. This would 
change the physicochemical property of the entrapped drug 
as reflected by improved dissolution behavior. Inclusion 
complexation have been long used as solubiliser and 
succeeded in enhancing the solubility of many poorly soluble 
drugs by their unique ability to form inclusion complexes 
with the hydrophobic drugs [20,23-25].
For trehalose binary system, the dissolution profiles are 
shown in Figure 3B and the extracted dissolution parameters 
are in Table 1. There was a significant (P < 0.05) increased in 
furosemide dissolution relative to unprocessed form (Figure 
3B & Table 1). At 1:1 ratio (FT1), about 64% of the drug was 
liberated after 10 minutes with a total release of 93% (Q90). 
Though this result less than that obtained from the same ratio 
using HP-γ-CD, but were similar to that of the marketed drug 
product (P < 0.05). It worth noting that, increasing trehalose 
content to 1:2 (FT2) and 1:5 (FT3), didn’t add significantly 
(P < 0.05) to drug dissolution rate. Therefore, 1:1 can be 
considered as the optimum weight ratio. The improved 
drug dissolution can be explained based on the formation of 
amorphous form or weakening of the crystalline structure of 
the drug crystals. This proposition can be supported by the 
DSC data. This, together with enhanced wettability by the 
close proximity with the hydrophilic trehalose molecules, can 
explain the improved dissolution parameters. Similar finding 
was reported where HP-γ-CD was superior to trehalose in 
enhancing the dissolution of Bendroflumethiazide [20]. 
With respect to marketed drug product, an initial release 
of 63% of loaded dose was noted followed by gradual drug 
dissolution (Figure 3). Compared to the solid dispersions, 
freeze dried formulations showed similar (FT1) or even 
better (FC1-3) dissolution behavior. This would rationalize 
the suitability of the adopted procedure as well as the 
selected carriers. 
To investigate the stability of the prepared formulation, 
formulations FCD3 and FT1 were stored at high temperature 
(40 ± 2°C) and relative humidity of 75% ± 5% for 6 months. 
After this period, dissolution studies were conducted. This 
quality test was selected for evaluation because dissolution 
pattern is critical as the aim of the prepared solid dispersion, 
employing lyophilization, was to produce formulations with 
fast drug dissolution suitable for example for preparation of 
oral dispersible tablets with subsequent rapid drug release. 
All tested samples containing either HP-γ-CD or trehalose 
were stable as there were no significant difference (P< 0.05) 
in release parameters compared to the freshly prepared 
samples. Hence, those excipients are promising to be applied 
with other hydrophobic drugs.
Conclusion
The dissolution rate is the determining step for oral 
absorption of the poorly water-soluble drugs. Because 
of poor dissolution and solubility of many drugs, their 
bioavailability is highly affected. Hence, dissolution and 
solubility enhancement became necessary task. Hydroxyl 
propyl-γ-cyclodextrin and Trehalose molecules are 
promising excipients for enhancing drug dissolution when 
subjected to lyophilization. Both excipients successfully 
enhanced the dissolution and solubility of the hydrophobic 
furosemide. The obtained solid dispersion was stable as 
reflected from similar dissolution parameters compared to 
freshly prepared samples. The optimum solid dispersion 
formulations can be formulated in the future into oral 
dispersible tablets. This tablet type is suitable for elderly 
patients whom are the most susceptible group for chronic 
diseases, including hypertension. 
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